Technologies

The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). Drug-resistance is a critical factor contributing to the gradual loss of clinical benefit to treatments for HIV infection. Accordingly, combination therapies have further evolved to address the mutating resistance of HIV. However, there has been great concern regarding the apparent growing resistance of HIV strains to current therapies. The present invention relates to human monoclonal antibodies to type 1 human immunodeficiency virus (HIV-1) envelope glycoprotein gp120, to phage display libraries, and to diagnostic methods and pharmaceutical compositions which employ these antibodies therapeutically and prophylactically.